Coexistence of Candida species and bacteria in patients with cystic fibrosis

Johanna Haiko 1 · Baharak Saeedi 1 · Gabriella Bagger 1 · Ferenc Karpati 2 · Volkan Özenci 1,3

Received: 14 November 2018 / Accepted: 21 January 2019 / Published online: 9 February 2019
© The Author(s) 2019

Abstract
Cystic fibrosis (CF) patients become colonized by pathogenic bacteria as well as by Candida species. The interplay between different microorganisms may play a key role in the prognosis of CF. The aim of the study was to analyze the coexistence patterns of bacteria and Candida spp. in sputum samples of patients with CF and to compare these patterns with the results of patients with other respiratory disorders (ORD). Sputum samples from 130 patients with CF and 186 patients with ORD were cultured on six different agar plates promoting the growth of bacteria and yeasts. Bacterial and Candida species were identified with MALDI-TOF MS. Pathogenic bacteria were found in 69.2% of the sputum samples of the CF patients, and in 44.1% the patients with ORD. CF patients tended to have growth of Pseudomonas aeruginosa and Staphylococcus aureus in sputum more often than patients with ORD. Overall, there was no difference in the coexistence of pathogenic bacteria and Candida spp. in these patient groups. However, when analyzed at the species level, P. aeruginosa and S. aureus coexisted with Candida spp. more frequently in sputum samples of CF patients compared with patients with ORD. Also, when analyzed according to age, it was shown that the adult (≥ 18 years) CF patients had a higher rate of coexistence of any pathogenic bacteria and Candida spp. than the children with CF and the adult patients with ORD. The rate for colonization with Candida together with pathogenic bacteria is increased in adult patients with CF.

Keywords Coexistence of yeast and bacteria · Candida spp. · Cystic fibrosis

Introduction
Cystic fibrosis (CF) is the most common monogenetic autosomal recessive disease in Northern Europe. The disease is caused by mutations in a cystic fibrosis transmembrane conductance regulator (CFTR) gene whose product is a chloride channel (Williams et al. [1]). CFTR mutations result in reduced excretion of chloride ions in the apical membrane of epithelial cells. Consequently, water absorption and viscid secretions increase, leading to defective mucociliary clearance. The disease affects mainly the epithelial cells in the intestine, respiratory system, pancreas, gall bladder, and sweat glands. Excessive mucus production and defective mucociliary clearance result in obstructive lung disease and chronic bacterial infections leading to respiratory failure, which is still the major cause of morbidity and mortality [2]. The colonization of the lower respiratory tract with microorganisms progresses with the duration of cystic fibrosis. In the early phases, the most common bacteria are Staphylococcus aureus and Haemophilus influenzae, whereas a wide range of bacteria, mainly Pseudomonas aeruginosa, Burkholderia cepacia complex, and other Gram-negative bacteria as well as fungal species, are isolated in the later stages of the disease [1]. There are several studies analyzing the prevalence of the pathogenic bacteria and fungi in patients with CF (for recent reviews, see [3–5]).

There is accumulating knowledge on the interplay between bacteria and yeasts. Recent studies have shown that the interaction between P. aeruginosa and Candida spp. can result in significant changes in the pathogenicity of P. aeruginosa [6–10]. Since P. aeruginosa is regarded as one of the most important pathogens in CF, detection and isolation of this
pathogen are routinely performed. In contrast, *Candida* spp. are generally considered as colonizers of the lower respiratory tract and regarded as not clinically relevant. Therefore, detection and identification of yeasts are performed occasionally.

There is limited data on the coexistence of viable bacteria and yeasts in the respiratory tract of CF patients [11, 12]. In addition, hitherto published studies have focused on describing the presence of yeasts and bacteria solely in patients with CF without comparing the data with patients with other respiratory diseases.

The aim of the present study was to document the coexistence of *Candida* spp. and pathogenic bacteria in the lower respiratory tract of the patients with CF and to compare these patterns with the patients with other respiratory disorders.

**Materials and methods**

**Sputum samples**

Clinical sputum samples used in this study were obtained from the patients with CF who are followed at the Stockholm CF Center at Karolinska University Hospital, Huddinge. Samples from the patients with other respiratory disorders were received mainly from the Lung and Allergy Clinic and rarely from Infectious Diseases Clinic for investigation for bacterial culture. The samples were cultured and processed at the Department of Clinical Microbiology, Karolinska University Hospital, Huddinge, Sweden, during a 9-week period in 2017.

**Culturing of sputum samples**

After sputolysin treatment, the sputum samples were inoculated on the following agar plates to identify the growth of pathogenic bacteria: chocolate agar, blood with crystal violet, cystine–lactose–electrolyte-deficient agar, *Pseudomonas* agar, and *Burkholderia cepacia* agar. The plates were incubated for 2 days at 35 °C in ambient air with the exception of the blood with crystal violet plates which were incubated in 5% CO₂. The agar plates mentioned above are standard media in the detection of pathogenic bacteria from clinical lower respiratory tract samples in our laboratory. To detect the growth of yeasts in the study material, the samples were also inoculated onto two selective agars to promote the growth of *Candida* spp.: Sabouraud dextrose (Becton Dickinson and Company) and chromogenic yeast agar (CHROMagar), which were incubated at 35 °C in ambient air for 5 days.

**Identification of microorganisms**

The colony morphology and the growth characteristics of the microorganisms that were detected on agar plates were visually evaluated. The bacterial colonies that were interpreted as clinically relevant were analyzed by MALDI-TOF MS. In addition, all the colonies that were grown on Sabouraud dextrose and CHROMagar were analyzed with MALDI-TOF MS for the identification of *Candida* spp. MALDI-TOF MS (Bruker Daltonics) analysis was performed according to the manufacturer’s instructions with the use of alpha-cyano-4-hydroxycinnamic acid (HCCA) matrix. Yeasts that did not give a valid result, i.e., with a score < 1.7, were treated with full ethanol-formic acid-acetonitrile extraction protocol and reanalyzed by MALDI-TOF MS.

Bacterial species that were regarded as clinically significant were *P. aeruginosa* and other *Pseudomonas* spp., *S. aureus*, *H. influenzae*, *Enterobacteriaceae*, *Stenotrophomonas maltophilia*, *Streptococcus pneumoniae*, *Moraxella catarrhalis*, *Achromobacter xylosoxidans*, *Burkholderia cepacia* complex, *S. pyogenes*, and *Neisseria meningitidis*.

**Statistical methods**

The presence of individual microorganisms and coexistence of bacteria and *Candida* spp. in adult CF patients, children with CF, and patients with other respiratory disorders were compared using the chi-square test. Fisher’s exact test was used when two individual patient groups were compared due to a lower sample size. The GraphPad Prism version 5.01 for Windows, GraphPad Software, San Diego, CA, USA (www.graphpad.com), was used for analysis. Values of *p* < 0.05 were statistically significant.

**Results**

In total, clinical sputum samples from 130 patients with CF and 186 patients with other respiratory disorders were included in the study. Only one sample per patient was analyzed. The patient characteristics are summarized in Table 1. The mean age of the CF patients and patients with other respiratory disorders were 25.9 and 59.0 years, respectively. In the CF group, 52/130 (40.0%) patients were children (<18). The data from children with CF and adult patients were also analyzed separately. In patients with other respiratory disorders, there were only 9/186 (4.8%) children. Due to the very low prevalence of children in patients with other respiratory disorders and no significant difference in the presence of different microorganisms in children and adults, the data were analyzed for all patients in this group. The proportion of males was 50.0% in the CF patients and 39.8% in the patients with other respiratory disorders.
**Growth of pathogenic bacteria**

Pathogenic bacteria, e.g., *P. aeruginosa* and other *Pseudomonas* species, *S. aureus*, *H. influenzae*, Enterobacteriaceae, *S. maltophilia*, *S. pneumoniae*, *M. catarrhalis*, *A. xylosoxidans*, *B. cepacia* complex, *S. pyogenes*, or *N. meningitidis*, were detected in 90/130 (69.2%) of the sputum samples of the CF patients, and in 82/186 (44.1%) of the samples of the patients with other respiratory disorders (*p* < 0.0001) (Fig. 1). When the patients with CF were analyzed according to age, there was no difference in the detection of pathogenic bacteria between adult (≥18 years) CF patients and children (<18 years) with CF, 59/78 (75.6%) and 31/52 (59.6%), respectively (*p* > 0.05, not significant). The adult CF patients had higher levels of pathogenic bacteria compared with patients with other respiratory disorders, 59/78 (75.6%) and 82/186 (44.1%), respectively (*p* < 0.0001). Children with CF had slightly higher levels of pathogenic bacteria compared with patients with other respiratory disorders, but this difference did not reach statistical significance, 31/52 (59.6%) and 82/186 (44.1%), respectively (*p* = 0.06, not significant) (Fig. 1).

When the three most common pathogenic bacterial species were analyzed, patients with CF had higher numbers of sputum samples with growth of *P. aeruginosa* than patients with other respiratory tract disorders, 51/130 (39.2%) and 32/186 (17.2%), respectively (*p* < 0.0001) (Table 2). The sputum cultures were positive for *S. aureus* in 29.2% of CF patients and only in 8.1% of the patients with other respiratory disorders (*p* < 0.0001). However, no difference was observed in the growth of *H. influenzae* between the two groups (*p* > 0.05, not significant) (Table 2).

**Growth of Candida spp.**

*Candida* spp. were detected in 73/130 (56.1%) CF patients and in 111/186 (59.7%) patients with other respiratory disorders (*p* > 0.05, not significant) (Fig. 1). The adult CF patients had higher levels of *Candida* spp. compared with children with CF, 51/78 (65.4%) and 22/52 (42.3%), respectively (*p* = 0.01). The children with CF had also lower levels of *Candida* spp. compared with other respiratory disorders, 42.3% and 59.7%, respectively (*p* < 0.05) (Fig. 1).

---

**Table 1** The characteristics of the patients with cystic fibrosis (CF) and other respiratory disorders included in the study

|                      | Cystic fibrosis (*n* = 130) | Other respiratory disorders (*n* = 186) |
|----------------------|-----------------------------|----------------------------------------|
| Gender               |                             |                                        |
| Male                 | 50.0%                       | 39.8%                                  |
| Female               | 50.0%                       | 60.2%                                  |
| Age                  |                             |                                        |
| ≥18 years            | 60.0%                       | 95.2%                                  |
| <18 years            | 40.0%                       | 4.8%                                   |
| Mean                 | 25.9 years                  | 59.0 years                             |
| Median               | 16.0 years                  | 60.0 years                             |

---

**Fig. 1** Detection of pathogenic bacteria, *Candida* spp., and coexistence of pathogenic bacteria and *Candida* spp. in sputum samples in patients with cystic fibrosis (CF) and other respiratory disorders. Pathogenic bacteria: *Pseudomonas aeruginosa*, *Staphylococcus aureus*, *Haemophilus influenzae*, Enterobacteriaceae, *Stenotrophomonas maltophilia*, *Streptococcus pneumoniae*, *Moraxella catarrhalis*, *Achromobacter xylosoxidans*, *Burkholderia cepacia* complex, *Streptococcus pyogenes*, *Neisseria meningitidis*, and *Pseudomonas* species
When the detection of Candida spp. was analyzed at the species level, we observed that C. albicans was the most common Candida species in our study material, with 53/130 (40.8%) in CF patient samples and 96/186 (51.6%) in the samples of patients with other respiratory disorders. The next most common Candida species were C. dubliniensis and C. glabrata (Table 3). Other Candida spp. were present in less than 20 (6.3%) samples altogether. More than one Candida species were detected in only 21/316 (6.6%) of the clinical samples.

**Table 2** The presence of three pathogenic bacterial species in the sputum samples of patients with CF and other respiratory disorders. Note that one patient may have more than one bacterial species.

| Patients (n)                  | P. aeruginosa, n (%) | S. aureus, n (%) | H. influenzae, n (%) |
|-------------------------------|----------------------|------------------|----------------------|
| CF (130)                      | 51 (39.2)            | 38 (29.2)        | 13 (10.0)            |
| CF < 18 years (52)            | 9 (17.3)             | 16 (30.8)        | 6 (11.5)             |
| CF ≥ 18 years (78)            | 42 (53.8)            | 22 (28.2)        | 7 (9.0)              |
| Other respiratory disorders (186) | 32 (17.2)          | 15 (8.1)         | 21 (11.3)            |

**Coexistence of Candida spp. and pathogenic bacteria**

Overall, in 103/316 (32.6%) clinical sputum samples, growth of both pathogenic bacteria and Candida spp. was observed. There was no significant difference between patients with CF and patients with other respiratory disorders in coexistence of Candida spp. and pathogenic bacteria, 49/130 (37.7%) and 54/186 (29.0%), respectively (p > 0.05, not significant). The adult CF patients had higher levels of coexistence of pathogenic bacteria and Candida spp. than patients with other respiratory disorders, 40/78 (51.2%) and 54/186 (29.0%), respectively (p < 0.001). The adult CF patients had also significantly higher levels of coexistence of pathogenic bacteria and Candida spp. than children with CF, 40/38 (101.3%) and 9/43 (17.3%), respectively (p < 0.001). There was no difference between children with CF and patients with other respiratory disorders in the coexistence of Candida spp. and pathogenic bacteria (p > 0.05, not significant) (Fig. 1).

We also analyzed the coexistence of Candida spp. with the three most common bacterial species in our material, i.e., *P. aeruginosa*, *S. aureus*, and *H. influenzae*. This approach revealed that *P. aeruginosa* coexisted with Candida spp. more frequently in the sputum samples of CF patients compared with the patients with other respiratory disorders, 29/130 (22.3%) vs. 22/186 (11.8%), respectively (p < 0.05; Table 4). Similarly, CF patients had higher coexistence levels of *S. aureus* with Candida spp. than the patients with other respiratory disorders, 17/130 (13.1%) vs. 11/186 (5.9%), respectively (p < 0.05). However, there was no difference in the levels of coexistence of *H. influenzae* with Candida spp. in these two patient groups (p > 0.05, not significant).

**Growth of only pathogenic bacteria and only Candida spp.**

Pathogenic bacteria, in the absence of Candida spp., were detected in 69/316 (21.8%) clinical samples included in the study. Patients with CF had higher levels of only pathogenic bacteria (i.e., in the absence of Candida spp.) compared with patients with other respiratory disorders, 41/130 (31.5%) and 28/186 (15.0%), respectively (p < 0.0001). Children with CF had higher levels of growth of only pathogenic bacteria compared with both adult CF patients and patients with other respiratory disorders, 22/252 (42.3%), 19/78 (24.3%), and 28/186 (15.1%), respectively (p < 0.05 and p < 0.0001, respectively). Adult CF patients and patients with other respiratory disorders had similar levels of growth of only pathogenic bacteria (p > 0.05, not significant) (Fig. 2).

Overall, only Candida spp. (i.e., in the absence of pathogenic bacteria) were isolated in 81/316 (25.6%) of the clinical samples. Patients with other respiratory disorders had higher levels of only Candida spp. compared with patients with CF, 57/186 (30.6%) and 24/130 (18.5%), respectively (p < 0.05). Adult CF patients and children with CF had similar levels of growth of only pathogenic Candida spp., 11/78 (14.1%) and 13/52 (25.0%), respectively (p > 0.05, not significant) (Fig. 2).

**Discussion**

Microorganisms tend to exist in multispecies communities in their ecological niches, including the human respiratory tract, and interact with each other in several ways. Hitherto ex vivo
studies have shown that these interactions may have both stimulatory and inhibitory effects for the virulence of the microorganisms. It is therefore important to analyze the levels of coexistence of clinically relevant bacteria and yeasts in individual diseases. However, there is limited information on the level of coexistence of the viable microorganisms in chronic diseases such as CF. In the present prospective study, we analyzed the presence of pathogenic bacteria and Candida spp. in clinical sputum samples by a culture-based method in patients with CF and patients with other respiratory disorders. Patients with CF were later divided into two groups as children and adults and further analyzed for the coexistence of pathogenic bacteria and Candida spp.

One-third (32.6%) of the patients included in the study had both pathogenic bacteria and Candida spp. in their lower respiratory tract. The adult CF patients had significantly higher levels of coexistence of pathogenic bacteria and Candida spp., both compared with the children with CF and with the patients with other respiratory disorders, 51.2%, 17.3%, and 29.0%, respectively ($p < 0.001$). The underlying reasons for the differences in these three groups in the coexistence of pathogenic bacteria and Candida spp. are probably multifactorial and complex.

It is known that the respiratory tract of the CF patients is most often colonized with different Candida spp. [11–14]. Candida spp. can be regarded as normal respiratory microbiota in moderate amounts and in immunocompetent individuals, but they are considered opportunistic pathogens, particularly in immunocompromised individuals, including CF patients. The role of Candida spp. in the pathogenesis of CF is, however, poorly understood. CF patients are increasingly treated with antifungal agents against molds [11], but they more often have long-term antibiotic treatment, and these aspects may explain the prevalence of Candida species. The detection of Candida spp. in patients with CF might also be related to other factors including the patients’ age and the duration of the disease.

In the present study, when the growth of Candida spp. was analyzed, the children with CF had significantly lower levels of Candida spp. compared with both adult CF patients and patients with other respiratory disorders, 42.3%, 65.4%, and 59.7%, respectively. Since the levels of Candida spp. were similar in adult CF patients and patients with other respiratory disorders, the present data suggest that the colonization of Candida spp. might be mainly due to the age of the patient.

When the presence of bacteria was analyzed, we observed that the adult CF patients had significantly higher levels of

| Table 4 Coexistence of Candida spp. and the three most common pathogenic bacterial species |
|---------------------------------------------------------------|
| Coexisting species                                      | CF ($n = 130$), $n (%)$ | Other respiratory disorders ($n = 186$), $n (%)$ |
|---------------------------------------------------------------|
| Candida spp. + P. aeruginosa                               | 29 (22.3)                     | 22 (11.8)                     |
| Candida spp. + S. aureus                                   | 17 (13.1)                     | 11 (5.9)                      |
| Candida spp. + H. influenzae                               | 5 (3.8)                       | 13 (7.0)                      |

![Figure 2](image_url)

**Fig. 2** Detection of only pathogenic bacteria, only Candida spp., and only normal flora in sputum samples in patients with cystic fibrosis (CF) and other respiratory disorders. Pathogenic bacteria: *Pseudomonas aeruginosa*, *Staphylococcus aureus*, *Haemophilus influenzae*, *Enterobacteriaceae*, *Stenotrophomonas maltophilia*, *Streptococcus pneumoniae*, *Moraxella catarrhalis*, *Achromobacter xylosoxidans*, *Burkholderia cepacia complex*, *Streptococcus pyogenes*, *Neisseria meningitidis*, and *Pseudomonas species*.
pathogenic bacteria compared with patients with other respiratory disorders, 75.6% and 44.1%, respectively. The present data suggest that the major difference between adult CF patients and patients with other respiratory disorders in the coexistence of pathogenic bacteria and *Candida* spp. might be due to the abundant presence of pathogenic bacteria in CF patients.

It was previously shown that *P. aeruginosa*, *S. aureus*, and *H. influenzae* are the most common pathogenic bacteria present in the lower respiratory tract of patients with CF [12, 15]. In line with these studies, we observed that CF patients had higher levels of *P. aeruginosa* and *S. aureus* compared with patients with other respiratory disorders, reflecting the importance of these two pathogens in CF.

Detection of *P. aeruginosa* has previously been correlated with the severity of CF [16], as well as with increased inflammation [17]. The existence of *P. aeruginosa* and *C. albicans*, together or alone, in the airways of CF patients, has been associated with worsened outcome of the lung function [18, 19]. Similarly, combinations of *P. aeruginosa* and *A. fumigatus*, *P. aeruginosa* and *S. maltophilia*, and *P. aeruginosa* and *B. cepacia* have been particularly associated with the loss of lung function in CF patients [20]. In the present study, we showed that the CF patients had higher levels of *P. aeruginosa* together with *Candida* spp. compared with patients with other respiratory disorders, 22.3% vs. 11.8%, respectively (p < 0.05). The interactions between *C. albicans* and bacteria at the molecular level have been shown to be complex. Chen et al. [8] showed that *C. albicans* produces ethanol, which in turn promotes both the colonization and biofilm formation of *P. aeruginosa*. In turn, however, *P. aeruginosa* forms a dense biofilm on *C. albicans* hyphae and kills the fungus [21]. *Candida* colonization of the respiratory tract was also shown to be common in patients receiving mechanical ventilation and was associated with prolonged ICU and hospital stays, and with an increased risk of *Pseudomonas* ventilator-associated pneumonia [22]. The clinical significance of the high levels of coexistence of *P. aeruginosa* and *Candida* spp. that were observed in the present study and their interaction with each other in patients with CF remains to be studied.

Both methicillin-susceptible *S. aureus* (MSSA) and methicillin-resistant *S. aureus* (MRSA) remain important pathogens both early and late in the disease course of CF [23]. Colonization by MRSA has been most strongly associated with lower lung function in CF patients [20]. The interaction between *S. aureus* and *C. albicans*, although not yet fully characterized, appears to be initially synergistic [24]. In the present study, we showed that CF patients had higher levels of *S. aureus* with *Candida* spp. than patients with other respiratory disorders, 13.1% vs. 5.9%, respectively (p < 0.05). It is important to note that none of the *S. aureus* isolates detected in this study were MRSA probably due to its very low prevalence in Sweden.

A majority of the recent studies on this subject have analyzed the microbiota at the molecular level. The major limitation of culture-based methods is their inability to detect non-culturable microorganisms. However, culture-based methods are reference methods in clinical routine for the detection of CF pathogens in the airways and enable the detection of viable microorganisms. In addition, molecular-based methods including next generation sequencing detect even low amounts of microorganisms, whereas the detection by culture-based methods requires high levels of microorganisms existing in the sample which probably reflects the clinical relevance of individual bacteria and yeast better.

It is important to analyze the coexistence of different microorganisms in individual chronic diseases. However, in the absence of comparison with other diseases, the interpretation of the data is inevitably limited. The present study is one of the first studies analyzing the coexistence of pathogenic bacteria and *Candida* spp. in patients with CF and comparing the data with a control group. The high existence of yeasts in the absence of high coexistence of pathogenic bacteria and yeasts in the control group indicates that colonization by *Candida* spp. does not exclusively lead to higher existence of pathogenic bacteria.

In general, it is difficult to find the optimal control group for CF patients. In the present study, patients with respiratory disorders other than CF were used as the control group. One of the limitations with this control group was that the controls were not age-matched with the CF patient group. However, the patients in the control group were from different lung and allergy units, suggesting that the patients had chronic respiratory tract diseases and may be compared with CF patients.

In conclusion, the present data show that CF is related to high levels of coexistence of pathogenic bacteria and *Candida* spp. Further studies are warranted to analyze the underlying reasons and the clinical relevance of the coexistence of pathogenic bacteria and *Candida* spp. described in the present study to guide relevant antifungal and antibacterial treatments for patients with CF.

**Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no conflict of interest.

**Ethical considerations** This study was performed ex vivo and did not include human participants. The clinical samples were taken for standard microbiological analysis and no additional samples were collected for this study. The existence of bacteria and yeasts in clinical samples was analyzed with the help of the laboratory information system. The results were not used in clinical decisions. Therefore, the study did not require ethical permission.

**Informed consent** The study did not require informed consent as mentioned above.
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

1. Williams C, Ranjendran R, Ramage G (2016) Pathogenesis of fungal infections in cystic fibrosis. Curr Fungal Infect Rep 10(4):163–169. https://doi.org/10.1007/s12281-016-0268-z

2. Rowntree RK, Harris A (2003) The phenotypic consequences of CFTR mutations. Ann Hum Genet 67(Pt 5):471–485

3. Frayman KB, Armstrong DS, Grimwood K, Ranganathan SC (2017) The airway microbiota in early cystic fibrosis lung disease. Pediatr Pulmonol 52(11):1384–1404. https://doi.org/10.1002/ppul.23782

4. Schwarz C, Hartl D, Eickmeier O, Hector A, Benden C, Durieu I, Sole A, Gartner S, Mill CE, Barry PJ (2018) Progress in definition, prevention and treatment of fungal infections in cystic fibrosis. Mycopathologia 183(1):21–32. https://doi.org/10.1007/s11046-017-0182-0

5. Singh A, Ralhan A, Schwarz C, Hartl D, Hector A (2018) Fungal pathogens in CF airways: leave or treat? Mycopathologia 183(1):119–137. https://doi.org/10.1007/s11046-016-0184-y

6. Gibson J, Sood A, Hogan DA (2009) Pseudomonas aeruginosa-Candida albicans interactions: localization and fungal toxicity of a phenazine derivative. Appl Environ Microbiol 75(2):504–513. https://doi.org/10.1128/AEM.01017-08

7. Morales DK, Hogan DA (2010) Candida albicans interactions with bacteria in the context of human health and disease. PLoS Pathog 6(4):e1000886. https://doi.org/10.1371/journal.ppat.1000886

8. Chen AI, Dolben EF, Okegbere C, Harty CE, Golub Y, Thao S, Ha DG, Willger SD, OToole GA, Harwood CS, Dietrich LE, Hogan DA (2014) Candida albicans ethanol stimulates Pseudomonas aeruginosa WspR-controlled biofilm formation as part of a cyclic relationship involving phenazines. PLoS Pathog 10(10)e1004480. https://doi.org/10.1371/journal.ppat.1004480

9. Fourie R, Ellis R, Swart CW, Sebolai OM, Albertyn J, Pohl CH (2016) Candida albicans and Pseudomonas aeruginosa interaction, with focus on the role of eicosanoids. Front Physiol 7:64. https://doi.org/10.3389/fphys.2016.00064

10. O’Brien S, Fothergill JL (2017) The role of multispecies social interactions in shaping Pseudomonas aeruginosa pathogenicity in the cystic fibrosis lung. FEMS Microbiol Lett 364(15). https://doi.org/10.1093/femsle/fnx128

11. Bakare N, Rickerts V, Bargon J, Just-Nübling G (2013) Prevalence of Aspergillus fumigatus and other fungal species in the sputum of adult patients with cystic fibrosis. Mycoses 46(1–2):19–23

12. Valenza G, Tappe D, Turnwald D, Froisch M, König C, Hebestreit H, Abele-Horn M (2008) Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. J Cyst Fibros 7(2):123–127

13. Güngör O, Tamay Z, Güler N, Erturun Z (2013) Frequency of fungi in respiratory samples from Turkish cystic fibrosis patients. Mycoses 56(2):123–129. https://doi.org/10.1111/j.1439-0507.2012.02221.x

14. Ziesing S, Suerbaum S, Sedlacek L (2016) Fungal epidemiology and diversity in cystic fibrosis patients over a 5-year period in a national reference center. Med Mycol 54(8):781–786. https://doi.org/10.1093/mmy/myw035

15. Kolak M, Karpati F, Monstein HJ, Jonasson J (2003) Molecular typing of the bacterial flora in sputum of cystic fibrosis patients. Int J Med Microbiol 293(4):309–317

16. Moran Losada P, Chouvarine P, Dorta M, Hedfeldt S, Mielke S, Schulz A, Viehlmann L, Tümmler B (2016) The cystic fibrosis lower airways microbial metagenome. ERJ Open Res 2(2):00096–02015

17. Zemanick ET, Wagner BD, Robertson CE, Ahrens RC, Chmiel JF, Clancy JP, Gibson RL, Harris WT, Kurland G, Laguna TA, McColley SA, McCoy K, Retsch-Bogart G, Sobush KT, Zeilin PL, Stevens MJ, Accurso FJ, Sagel SD, Harris JK (2017) Airway microbiota across age and disease spectrum in cystic fibrosis. Eur Respir J 50(5):1700832. https://doi.org/10.1183/13993003.00832-2017

18. Chotirmall SH, ODonohue E, Bennett K, Gunaratnam C, O’Neill SJ, Mcelvaney NG (2010) Sputum Candida albicans presages FEV1 decline and hospital-treated exacerbations in cystic fibrosis. Chest 138(5):1186–1195

19. Navarro J, Rainisio M, Harms HK, Hodson ME, Koch C, Mastella G, Strandvik B, McKenzie SG (2001) Factors associated with poor pulmonary function: cross-sectional analysis of data from the ERCF. European Epidemiologic Registry of Cystic Fibrosis. Eur Respir J 18(2):298–305

20. Hector A, Kim T, Ralhan A, Graepler-Mainka U, Berenbrinker S, Riemthuemer J, Hogardt M, Wagner M, Pfleger A, Autenrieth I, Kappler M, Griese M, Eber E, Martin P, Hartl D (2016) Microbial colonization and lung function in adolescents with cystic fibrosis. J Cyst Fibros 15(3):340–349. https://doi.org/10.1016/j.jcf.2016.01.004

21. Hogan DA, Kolter R (2002) Pseudomonas-Candida interactions: an ecological role for virulence factors. Science 296(5576):2229–2232

22. Azoulay E, Timsit JF, Tafflet M, de Lassence A, Darmon M, Zahar JR, Adrie C, Garrouste-Orgeas M, Cohen Y, Mourvillier B, Schlemmer B, Outcomerea Study Group (2006) Candida colonisation of the respiratory tract and subsequent pseudomonas ventilator-associated pneumonia. Chest 129(1):110–117

23. Goss CH, Muhlebach MS (2011) Review: staphylococcus aureus and MRSA in cystic fibrosis. J Cyst Fibros 10(5):298–306. https://doi.org/10.1016/j.jcf.2011.06.002

24. Sherritt ME, Peters BM, Jabra-Rizk MA (2009) Cross-kingdom interactions: Candida albicans and bacteria. FEMS Microbiol Lett 299(1):1–8. https://doi.org/10.1111/j.1574-6968.2009.01668.x